Schizophrenia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
- $ 2500
- May 2024
- 295 pages
Rituximab intravenous formulation is indicated for the treatment of previously untreated adult patients with stage III-IV follicular lymphoma in combination with chemotherapy; as maintenance therapy is indicated for the treatment of adult follicular lymphoma patients responding to induction therapy; as monotherapy indicated for treatment of adult patients with stage III-IV follicular lymphoma who are chemoresistant or are in their second or subsequent relapse after chemotherapy; for the treatment of adult patients with CD20 positive diffuse large B cell non-Hodgkin s lymphoma in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy; in combination with chemotherapy is indicated for the treatment of paediatric patients (aged = ## months to ## years old) with previously untreated advanced stage CD20 positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL)/Burkitt leukaemia (mature B-cell acute leukaemia) (BAL) or Burkitt-like lymphoma (BLL) and for the treatment of patients with previously untreated and relapsed/refractory CLL. Rituximab in combination with methotrexate is indicated for the treatment of adult patients with severe active rheumatoid arthritis who have had an inadequate response or intolerance to other disease-modifying anti-rheumatic drugs (DMARD) including one or more tumour necrosis factor (TNF) inhibitor therapies; in combination with glucocorticoids, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (Wegener s) (GPA) and microscopic polyangiitis (MPA); in combination with glucocorticoids, is indicated for the induction of remission in paediatric patients (aged = ## to ## years old) with severe, active GPA (Wegener s) and MPA and for the treatment of patients with moderate to severe pemphigus vulgaris (PV). [...] Rituximab subcutaneous formulation is indicated in adults for Non-Hodgkin s lymphoma (NHL): for previously untreated patients with stage III-IV follicular lymphoma in combination with chemotherapy; as maintenance therapy is indicated for the treatment of follicular lymphoma patients responding to induction therapy and for the treatment of patients with CD20 positive diffuse large B cell non-Hodgkin s lymphoma in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy. [...] It is under development for neuromyelitis optica (Devic s syndrome),post-transplant lymphoproliferative disorder, refractory chronic inflammatory demyelinating polyneuropathy (CIDP), fibrillary glomerulonephritis, systemic sclerosis, melanoma, mucosa-associated lymphoid tissue lymphoma, schizophrenia spectrum disorder and obsessive-compulsive disorder and for paediatric patients with severe, active GPA (Wegener s), marginal zone B-cell lymphoma, nodal marginal zone B-cell lymphoma, extranodal marginal zone B-cell lymphoma (mucosa-associated lymphoid tissue or MALT- lymphoma), splenic marginal zone B-cell lymphoma, microscopic polyangiitis (MPA), previously untreated advanced stage CD20 positive diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL)/Burkitt leukaemia (mature B-cell acute leukaemia) (BAL) or Burkitt-like lymphoma (BLL).